Let's connect

Want to discuss your project or have any questions?

Protein binding and blood partitioning

Fraction unbound and drug distribution

Unbound drug concentration is the major driver of in vitro and in vivo efficacy of drug candidates. Determining the unbound fraction of a drug in plasma, tissue homogenates or assay medium is essential from early to late-stage drug development. Our extensive experience in in vitro distribution studies helps ensure high-quality data you can rely on.

A scientist uses a multifiller to dispense liquid into a rack of vials in a laboratory setting.

Protein binding

Plasma protein binding is crucial for understanding the pharmacokinetic behavior and pharmacological/toxicological effects of a drug. The binding of drug candidates in plasma from various species, or to isolated proteins such as human serum albumin or α-acid-glycoprotein, is determined by equilibrium dialysis or ultracentrifugation. Our in vitro assay may include an investigation of concentration dependency in binding across all matrices.

Blood partitioning

The concentration ratio of drugs in whole blood versus plasma indicates drug binding to erythrocytes. This is important when comparing clearance estimates directly with organ blood flow rates, such as in the liver, to determine the organ clearance extraction ratio. Our whole blood distribution assay determines the blood-to-plasma ratio for scaling purposes (IVIVE) and estimating hepatic first-pass extraction by converting plasma into blood clearances. These data guide the selection of the most appropriate matrix for pharmacokinetic in vivo studies. Both in vitro distribution studies can be conducted with either radiolabelled or unlabelled test compounds, using liquid scintillation counting or tandem mass spectrometry for quantification, respectively.

Contact us

Nuvisan is committed to protecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Talk to us

talk icon
+49 731 9840 0 

Our locations

location icon

Neu-Ulm (headquarters)

Wegenerstrasse 13

89231 Neu-Ulm

Germany

Berlin

Muellerstrasse 178

13353 Berlin

Germany

Sophia Antipolis

2400 route des Colles

06410 Biot

France

Grafing

Am Feld 32

85567 Grafing

Germany

Waltrop

Im Wirrigen 25

45731 Waltrop

Germany

For concerns about pharmaceuticals or adverse drug-related events, contact us at: complaints@nuvisan.com